Frontlight ResearchEarly access
CompletedNo phase
Gender-based Differences in the Outcome of the Treatment of Persistent Septic Shock With Hydrocortisone
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 621 people enrolled
- Started
- 1 Jan 2023
- Ended
- 1 Aug 2024
- Type of study
- Observational, 2 groups
- Record updated
- 6 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Adult patients of both sexes with persistent septic shock received hydrocortisone during their intensive care unit (ICU) stay
Who cannot take part
- Patients with incomplete data sets
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to explore the gender-based differences in the outcomes of treatment with hydrocortisone in critically ill patients with persistent septic shock.
The 2 groups in the trial
- The Female Group
Patients are categorized as females according to their apparent gender.
- The Male Group
Patients are categorized as males according to their apparent gender.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Impact of sex on outcomes in septic shock patients treated with hydrocortisone.Scientific reports, 2025
- Record updated
- 6 August 2024